Specialty Pharmacies

Analysis

340B Contract Pharmacy Restrictions: What Manufacturers and Vendors Need to Know in 2026

2026 field guide to 340B contract pharmacy restrictions: manufacturer policies, Eighth/Third/D.C. Circuit rulings, state laws, the vacated rebate pilot, and vendor selection impact.

Analysis

340B TPA Comparison: Apexus vs Sentry Data Systems vs Macro Helix

Covered-entity 340B TPA comparison for Apexus, Sentry Data Systems, and Macro Helix, with manufacturer channel-risk implications.

Analysis

Big Three PBM Specialty Pharmacy Operations

The Big Three PBM specialty pharmacies are not simply large dispensing vendors; they are vertically integrated control points that combine formulary leverage, network steering, specialty fulfillment, copay/maximizer economics, and private-label biosimilar strategy.

Comparison

Big-3 Specialty Pharmacy: CVS Specialty vs Accredo vs OptumRx Specialty

Head-to-head comparison of the three PBM-owned specialty pharmacies that collectively dispense ~66% of U.S. specialty drug revenue.

Analysis

Biosimilar Launch Playbook: Hub, Copay & SP Strategy

Analysis of the hub services, copay assistance, and specialty pharmacy strategy specific to biosimilar launches — a structurally different commercial model from innovator biologics that requires recalibrated vendor selection, program design, and economic assumptions.

Analysis

Contract Development & Manufacturing Organizations (CDMOs): Cold Chain, Cell & Gene, Biologic Fill-Finish in 2026

CDMO market sizing, tiered competitive landscape, BIOSECURE Act implications, cell/gene and fill-finish capacity, and a selection framework for biotech launch teams evaluating manufacturing partners.

Analysis

Cell & Gene Therapy Commercialization: The Services Landscape in 2026

The CGT vendor stack is categorically different from specialty biologics. FACT sites, cryo-chain logistics, one-time pricing, and outcomes-based contracts reshape every service line.

Analysis

Cell and Gene Therapy Services Comparison: Orsini vs PANTHERx vs Onco360 vs Accredo vs CVS

This comparison supports a manufacturer-side CGT launch decision: which specialty-pharmacy and access partner can handle product-specific requirements around cryogenic handling, REMS, treatment-center coordination, payer access, hub orchestration, and long-term follow-up.

Analysis

Conflict of Interest in Pharma Commercial Services: A Manufacturer's Framework

Conflict of interest is now a core vendor-selection variable in pharma commercialization, not a legal afterthought. PBM-owned specialty pharmacies, distributor-owned hubs, full-stack commercialization platforms, copay maximizer operators, and data-rich service vendors can all create value through integration, but the same integration can redirect prescriptions, obscure economics, constrain data rights, or weaken manufacturer control over the patient journey.

Comparison

Pharma Copay Program Vendors: ConnectiveRx vs Valeris vs Phil vs Apollo Care

Head-to-head comparison of four copay and financial assistance platforms for pharmaceutical manufacturers. Spans legacy per-redemption processors to digital-first orchestration.

Analysis

EVERSANA Patient Services: Full-Stack Commercialization Model

This analysis is derived from EVERSANA's Patient Services General Capabilities Deck (2024), a 49-page presentation detailing their integrated patient services and commercialization platform. EVERSANA represents the most complete example of a "full-stack" pharma commercialization partner -- a model that bundles advisory, field deployment, patient services, specialty pharmacy, market access, and data analytics under one roof.

Guide

Field Reimbursement Managers (FRMs): What They Do, Cost, and How to Deploy

Operator guide to FRM programs: functions, loaded-cost modeling, territory sizing, deployment vendors, hub integration, and ROI measurement for specialty launches.

Analysis

GLP-1 Services Crunch: Which Pharma Services Vendors Scale to 10M Patients?

Institutional analysis of which pharma services vendors can scale to GLP-1 volumes. Hubs, AI-PA, retail shift, DTC/telehealth, compounding, and the 2027 IRA reset.

Comparison

Health System SP Accelerators: Shields vs Clearway Health vs CarePathRx vs CPS Solutions

Buyer comparison of the four most relevant health-system specialty pharmacy accelerators in 2026, focused on independence, stack breadth, and structural channel risk.

Analysis

Health System Specialty Pharmacy: Build vs. Buy vs. Partner

The 2019-2023 "build your own specialty pharmacy" playbook for health systems no longer describes the 2026 decision. The defining event reframing the calculus was originally Walgreens' August 28, 2025 divestiture of Shields Health Solutions to Sycamore Partners, financed in part by $3.5B of preferred equity from Evernorth (Cigna/Express Scripts). But that event did not stand alone.

Analysis

Health System Specialty Pharmacy Economics

Health system specialty pharmacies are the fastest-growing channel in specialty drug distribution, expanding from 15% to 27% of URAC-accredited SP locations between 2017 and 2024. The growth is driven by a single economic force: 340B Drug Pricing Program margin capture.

Comparison

Home Infusion Platforms: CVS Coram vs Option Care Health vs Naven Health

Head-to-head comparison of the three dominant home and alternate-site infusion models biotech commercialization teams evaluate when planning IV/SC biologic launches.

Analysis

Hub Services Pricing Benchmarking: What Should Manufacturers Pay?

Hub pricing is opaque because vendors price capacity, transactions, patients, technology, and outcomes in different combinations, while manufacturers often benchmark proposals too late in the launch process. The practical thesis is that hub cost should be evaluated against workflow complexity and revenue impact, not against a generic rate card.

Analysis

IRA Maximum Fair Price: What Rounds 2-3 Mean for Hub, Copay, and Specialty Pharmacy Vendors

How IRA Medicare negotiation Rounds 2-3 (2027-2028 MFPs) restructure vendor economics across hubs, copay, specialty pharmacy, 340B, and market access consulting.

Comparison

Market Access Consulting Deep Dive: Pricing, GTN, IRA Modeling, and How Top Firms Differ in 2026

Deep dive on market access consulting: firm tiers, typical engagement pricing, IRA MFP modeling, GTN waterfall work, and how Trinity, Avalere, Precision AQ, ZS, Bain, and others differ.

Guide

Oncology Launch: Vendor Stack Playbook for Commercial Teams

The vendor stack for an oncology launch: hub services, specialty pharmacy, field reimbursement, RWE, and medical affairs, mapped by route of administration.

Analysis

Oncology Pharmacy Network Design: LDD Segmentation and Specialty Pharmacy Selection

This analysis gives manufacturer launch teams a practical oncology specialty pharmacy network design framework: when to use Onco360, when to include PBM-owned SPs, when health-system pharmacies matter, and when independent specialists or rare-disease pharmacies should be in the network.

Analysis

Part D Redesign 2025-2026: The End of Copay Accumulators and the New Patient Economics

How the 2025 Part D redesign, $2,000 OOP cap, Manufacturer Discount Program, and smoothing rewrite manufacturer economics and neutralize accumulator value.

Analysis

Payer Landscape Overview: Plan Design, Self-Insured Dynamics & Formulary Strategies

Analysis of the U.S. commercial and government payer landscape as it relates to pharmaceutical services vendor selection. This page provides the demand-side context that shapes hub services, copay assistance, specialty pharmacy, and prior authorization vendor requirements.

Analysis

PBM-Owned vs Independent Specialty Pharmacy Competitive Analysis

PBM-owned specialty pharmacies dominate by structural control over formulary, network, and captive lives; independent and health-system specialty pharmacies compete on clinical depth, manufacturer alignment, data transparency, and limited-distribution execution. For manufacturers, the optimal network is therefore product-specific rather than ideology-specific.

Analysis

PBM Reform 2026: What CAA, FTC, State Divestitures, and Transparency Rules Mean for Pharma Vendor Strategy

How the FTC Express Scripts settlement, CAA 2026, Arkansas Act 624, and federal delinking proposals are reshaping specialty pharmacy, hub services, and manufacturer GTN strategy.

Analysis

PBM Reform Implications for Pharma Services Vendors

PBM reform is accelerating across federal, state, and regulatory levels. The convergence of the FTC investigation, Consolidated Appropriations Act of 2026 (CAA), state PBM divestiture legislation, and copay accumulator/maximizer restrictions is reshaping the competitive landscape for every pharma services vendor category. This analysis maps the specific implications for hub services, specialty pharmacies, copay assistance vendors, and market access consultants.

Analysis

PBM Transparency & Pass-Through Economics

Big 3 PBM opacity economics — spread pricing, rebate retention, self-preferencing to affiliated specialty pharmacies — face the most serious structural threat since the modern PBM model emerged in the early 2000s.

Guide

Pharma Services Explained: Hub, Specialty Pharmacy, FRM, and How They Fit Together

Lexicon guide to the pharma commercial services stack. Hub vs specialty pharmacy vs field reimbursement vs copay processor vs market access, with pricing models and named vendors.

Analysis

US Pharma Services Market Sizing and 2025 Update

Directional U.S. pharma services market sizing across specialty pharmacy, prior authorization and reimbursement support, copay programs, market access consulting, data/RWE, and commercial technology, with the 2025 banking-report update folded into one public market map.

Guide

Rare Disease Launch: Vendor Stack Playbook

A prescriptive vendor-stack playbook for rare disease launch teams — sequenced T-18 to T+6 with named vendors, pricing benchmarks, and decision trade-offs for orphan drug commercialization.

Comparison

Rare Disease SP Comparison: PANTHERx vs Orsini

Head-to-head comparison of the two leading independent rare disease specialty pharmacies in the United States. PANTHERx Rare and Orsini Specialty Pharmacy represent different approaches to the same niche: pure-play rare disease scale vs. integrated hub+SP+3PL with cell/gene therapy leadership. This comparison is the most important decision point for orphan drug manufacturers selecting a dedicated rare disease pharmacy partner.

Guide

Regulatory Consulting for Pharma: FDA Submission Support, REMS, and Post-Market Surveillance

Guide to pharma regulatory consulting firms. Scope, firm tiers (scale CROs, boutiques, law-adjacent), day rates, engagement models, REMS, PVG, and when to choose which partner.

Analysis

Specialty Pharmacy Competitive Landscape

U.S. specialty pharmacy landscape analysis covering PBM-owned scale platforms, independent clinical specialists, and health-system specialty pharmacy growth.

Analysis

Therapeutic Area Specialization Guide: How Hub and SP Workflows Differ by Disease

Therapeutic area specialization is the most common source of false comparability in hub and specialty-pharmacy RFPs. Oncology, rare disease, autoimmune, GLP-1/metabolic, and CGT programs use overlapping vendor categories, but the work is fundamentally different: buy-and-bill versus pharmacy benefit, high-touch case management versus high-volume automation, oral adherence versus chain-of-identity logistics, and biosimilar/formulary defense versus patient finding.

Listicle

Top 12 Real-World Evidence (RWE) Vendors for Pharma in 2026

Ranking of the 12 leading real-world evidence vendors for pharma in 2026, covering claims, EHR, genomic, patient-reported, and integrated RWD providers.

Listicle

Top 10 Specialty Pharmacies for Pharma Manufacturers (2026)

Ranking and analysis of the top 10 specialty pharmacies serving pharma manufacturers, covering PBM-owned, independent, payer-owned, retail-adjacent, and health-system accelerator models.

Analysis

Vertical Integration Economics in Pharma Services

Vertical integration creates real operating value but transfers bargaining power and data control away from manufacturers. PBM/SP/insurer stacks, distributor/hub/pharmacy stacks, and full-stack commercialization platforms all promise fewer handoffs, richer data, and simpler accountability.